Shared on04 Sep 25
With Daiichi Sankyo's net profit margin and future P/E multiples both effectively unchanged, analysts have maintained their consensus price target at ¥5459. What's in the News DATROWAY (datopotamab deruxtecan) approved in China for HR positive, HER2 negative breast cancer after prior endocrine and chemotherapy, jointly developed with AstraZeneca.
Shared on17 Apr 25Fair value Decreased 0.14%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 3.79%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Increased 5.73%
AnalystConsensusTarget has decreased future PE multiple from 32.6x to 28.8x.